Bone and Cancer Working Group

Members

Chair: R Rizzoli     
Members: JJ Body,  ML Brandi, M Campusano, J Cannata-Andia, M Chakhtoura, D Chappard, C Confavreux, P Ebeling, G El Hajj Fuleihan, A El Maghraoui, C Glüer, G Guglielmi,  P Hadji, G Holzer, D Kendler, N Napoli, A Papaioannou, T de Villiers
 

Projects

Hematologic stem cell transplant and bone loss: Bone loss and its management in relation to bone marrow transplant and in response to chemotherapy and glucocorticoid treatment.

Cancer in children: Bone loss and it management in relation to cancer in children and adolescents and in response to chemotherapy, radiation and surgery.

Optimal duration of bone targeting agent (BTA) administration in patients with tumor bone disease: Questions to be answered: when to start? When to stop? When to decrease the treatment intensity? With a focus on bone metastasis and not myeloma.

Evaluation of risk of fractures in bone metastasis (prostate cancer): Evaluation of the skeletal rare events with specific attention to the quality of life, metabolic consequences, muscle function and sarcopenia of patients suffering cancer.

New treatments in multiple myeloma: To review the bone effects of the new treatments in the management of multiple myeloma.

Publications

R Rizzoli, JJ Body,  ML Brandi, J Cannata-Andia, D Chappard, A El Maghraoui, C C Glüer, D Kendler, N Napoli, A Papaioannou, DD Pierroz,  M Rahme, CH Van Poznak, TJ de Villiers, G El Hajj Fuleihan for the International Osteoporosis
Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease (2013) Cancer-associated bone disease. Osteoporos Int 2013 DOI 10.1007/s00198-013-2530-3
http://link.springer.com/article/10.1007/s00198-013-2530-3

P Hadji, M S Aapro, JJ Body, M Gnant, ML Brandi, JY Reginster, M Carola Zillikens, CC Glüer, T de Villiers, R Baber, G D Roodman, C Cooper, B Langdahl, S Palacios, J Kanis, N Al-Daghri, X Nogues, E Fink Eriksen, A Kurth, R Rizzoli, RE Coleman. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology, Vol. 7, June 2017, Pages 1-12. http://doi.org/10.1016/j.jbo.2017.03.001 http://www.sciencedirect.com/science/article/pii/S2212137417300258